Please assess the completion status of the following clinical trial:

Trial Title: US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of advanced upper lobe predominant emphysema~* age \>/= 40 years~* clinically significant dyspnea~* failure of standard medical therapy to relieve symptoms (inhaled beta agonist and inhaled anticholinergic)~* pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 \< 45% predicted and experiencing \< 30% or 300 mL improvement using bronchodilator; TLC \> 110% predicted; RV \> 150% predicted)~* 6 Minute Walk Distance \>/= 150 m~Exclusion Criteria:~* alpha-1 protease inhibitor deficiency~* homogeneous disease~* tobacco use within 4 months of initial visit~* body mass index \< 15 kg/m2 or \> 35 kg/m2~* clinically significant asthma, chronic bronchitis or bronchiectasis~* allergy or sensitivity to procedural components~* pregnant, lactating or unwilling to use birth control if required~* prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endobronchial valve placement, airway stent placement or pleurodesis~* comorbid condition that could adversely influence outcomes~* inability to tolerate bronchoscopy under conscious sedation (or anesthesia)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLVR Treatment (Type: EXPERIMENTAL): BLVR Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).